Photothermal-chemotherapy (PT-CT) is a promising strategy for cancer treatment, but its development is hindered by the issues regarding to the long-term safety of carriers and imperfect drug release profiles. In this article, we use polyethylene glycol-modified polydopamine nanoparticles (PDA-PEG) as an outstanding PT-CT agent for cancer treatment. PDA-PEG possesses excellent biocompatibility and photothermal effect, and could easily load anticancer drugs such as doxorubicin (DOX) and 7-ethyl-10-hydroxycamptothecin (SN38) via π-π stacking and/or hydrogen binding. Moreover, the drug-loaded PDA-PEG showed great stability and drug-retaining capability in physiological condition, and could respond to multiple stimuli including near infrared light, pH and reactive oxygen species to trigger the release of loaded anticancer drugs. The in vitro and in vivo studies demonstrated that PDA-PEG-mediated PT-CT showed synergetic effect for cancer therapy.
Keywords: Multi-responsive drug release; Photothermal-chemotherapy; Polydopamine; Synergetic effect.
Copyright © 2015 Elsevier Ltd. All rights reserved.